KLP Kapitalforvaltning AS Raises Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

KLP Kapitalforvaltning AS boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 17.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 30,200 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,500 shares during the period. KLP Kapitalforvaltning AS’s holdings in Collegium Pharmaceutical were worth $901,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of COLL. New Age Alpha Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 4th quarter worth $40,000. Wealthquest Corp purchased a new stake in Collegium Pharmaceutical during the first quarter valued at about $62,000. Virtus Fund Advisers LLC boosted its position in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares during the period. FORA Capital LLC purchased a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $223,000. Finally, XTX Topco Ltd bought a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $236,000.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 5th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $43.75.

Collegium Pharmaceutical Trading Down 1.3%

Shares of Collegium Pharmaceutical stock opened at $31.36 on Tuesday. The company’s 50-day moving average price is $30.39 and its 200-day moving average price is $29.74. The company has a current ratio of 1.08, a quick ratio of 1.01 and a debt-to-equity ratio of 3.30. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The company has a market cap of $1.01 billion, a price-to-earnings ratio of 25.70 and a beta of 0.64.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same period last year, the company posted $1.45 EPS. The business’s revenue was up 22.7% on a year-over-year basis. On average, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its board has authorized a stock repurchase plan on Monday, July 7th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the sale, the director owned 70,658 shares in the company, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.